Acadia Pharmaceuticals | ACAD - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
ALKERMES USD 4.39B 135.05M 2026-06
Alnylam Pharmaceuticals USD 5.56B 429.22M 2026-06
Biogen USD 32.09B 2.6B 2026-06
BioMarin Pharmaceutical USD 11.72B 3.13B 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Cara Therapeutics USD 25.82M 6.26M 2026-03
Corcept Therapeutics USD 888.7M 73.82M 2026-06
Cytokinetics USD 1.92B 651.07M 2026-06
Eisai JPY 1.56T 108.98B 2026-06
Eli Lilly USD 142.28B 25.71B 2026-06
Incyte USD 7.87B 533.53M 2026-06
J&J USD 201.06B 167M 2026-06
Moderna USD 10.96B 527M 2026-06
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
Pfizer USD 201.13B 6.49B 2026-06
Prothena USD 302.58M 47.32M 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Sarepta Therapeutics USD 3.19B 9.58M 2026-06
Ultragenyx Pharmaceutical USD 1.26B 32M 2026-06
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12
Vertex Pharmaceuticals USD 27.42B 938.9M 2026-06